Kimon Angelides

Serial Entrepreneur and founder of EosHealth (renamed Livongo)

CEO and Founder, FemTec Health
Founder and CEO, EarlyBird Pharma
Managing Partner, Ithaca LifeScience Partners Investment Fund
Founder EosHealth (renamed Livongo)

Kimon Angelides is the founder of six healthcare companies: FemTec Health, Merlin LifeSciences, Vivante Health, EosHealth renamed Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently to be acquired for $18.5B by Teladoc, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment and provider risk models, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

Kimon recently received the digital health Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine. Kimon’s newest company, FemTec Health brings together the best in science-based products and digital health to serve the total healthcare needs of women, using a multidisciplinary approach using digital therapeutics, diagnostics and discovery medicine, devices, AI and deep learning, and analytics.

Prior to his healthcare career, Kimon led strategy for Tanox, Inc., a biotech company now part of Genentech, Director of Strategic Development at Heart Institute, Professor and Chair of Cell Biology at the University of Durham in the UK building the pre-clinical services for a new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate Professor at the University of Florida and McGill University. Kimon has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was a Research Career Development Awardee of the National Institutes of Health, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 60 patents. He has a PhD in Bio-organic Chemistry from the University of California and has graduate degrees in business, laws, and public health.

Kimon Angelides